

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 13th September 2018 8:15am – 9:30am
Venue	The Committee Room, Alderson House, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics (via speakerphone until 9am) Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via speakerphone) Dr S Raise, GP ER CCG (via speakerphone) Dr O Ogunbambi, Consultant Rheumatologist Dr H Klonin, Consultant Paediatrician Mr R Kapur, Vascular Surgeon (until 9am) Dr F Umerah, Consultant Anaesthetist
Apologies	Prof A Morice, Chair, Professor of Respiratory Medicine Dr A Samson, Infectious Diseases Consultant

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.09.01	Apologies	As above.					
2018.09.02	Declarations of Interest	None.					
2018.09.03	Minutes of the previous meeting	Accepted as a true record.	Approved.				9/18
2018.09.04	Action Tracker	<p>Minutes The minutes from the August meeting have been updated.</p> <p>Fendix Media Advertising Campaigns on Pattie Intranet DC to seek feedback on advertising and from web services on number of hits and if the Trust has benefitted. DC to discuss when AM is present.</p> <p>Tracker ML to submit application for atezolizumab.</p> <p>New Process for Oncology Requests POB updated the committee that SS has taken the new process to the oncology consultants meeting, but as yet no paperwork has filtered through to D&TC.</p> <p>NICE Guidance ML to request applications for midostaurin TA523, atezolizumab TA525 and arsenic trioxide TA526.</p> <p>NICE Guidance Glatiramer has been added to formulary.</p> <p>MHRA DSU ML has discussed densoumab with colleagues</p> <p>E-Cigs/Vapes</p>	<p>Action complete.</p> <p>Ongoing.</p> <p>Ongoing.</p> <p>To be reviewed in Jan 19.</p> <p>Ongoing.</p> <p>Action complete.</p> <p>Action complete.</p>	<p>DC to update in October</p>	<p>DC</p> <p>ML</p> <p>SS/SG</p> <p>ML</p>	<p>9/18</p> <p>8/18</p> <p>1/19</p> <p>8/18</p>	<p>9/18</p> <p>9/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>POB has discussed updating the Trust PGD with smoking cessation team and AC. This is because the current PGD requires the primary assessment to take place in the community pharmacy who will supply cessation products, therefore if assessment has taken place at HEY PGD cannot be followed and patients are disadvantaged.</p> <p>E-Cigs/Vapes POB has requested AC to write paper regarding CQUIN/Smoking Cessation/E-cigs</p> <p>The use of E-cigs/Vapes is a current recommendation from PHE in support of helping patients to quit smoking. RK informed the committee that the vascular surgeons preferred that patients did not use e-cigs/vapes on hospital grounds.</p> <p>AOB Use of levosimendan out of hours has been escalated to cardiothoracic governance meeting.</p> <p>AOB Out of hours flow chart has been drafted and will be circulated for discussion at the next D&TC meeting.</p> <p>New Product Requests AM has written to applicants and WH has updated the formulary and unlicensed list.</p> <p>New Product Requests POB has asked AR to discuss dupilumab with dermatology and ask for a pathway. Dermatology have informed him that they will only be using dupilumab to treat very severe disease not moderate to severe as recommended on the NICE TA. KMcC was due to meet with AR & POB/DC soon to discuss further.</p> <p>NICE Guidance SG has written to Mr Achawal re NG99. Application for 5 amino levulonic acid is on the agenda for discussion.</p>	<p>Action complete.</p> <p>Ongoing - discuss in October.</p> <p>Action complete.</p> <p>Discuss in October.</p> <p>Action complete.</p> <p>Action complete.</p> <p>Action complete.</p>		<p></p> <p>POB</p> <p></p> <p>POB</p> <p></p> <p></p>	<p></p> <p>9/18</p> <p></p> <p>8/18</p> <p></p> <p></p>	<p>9/18</p> <p></p> <p>9/18</p> <p>9/18</p> <p>9/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		NICE Guidance NG100 WH has added barecetinib to formulary.	Action complete.				9/18
		NICE Guidance ML to request application for atezolizumab in line with TA492.	Ongoing.		ML	9/18	
		NICE Guidance ML to request application for niraparib in line with TA528.	Ongoing.		ML	9/18	
		NICE Guidance WH has checked that crizotinib is already in use, so has added to the formulary.	Action complete.				9/18
		MHRA DSU AM has written to haematology regarding eltrombopag and reports of interference with test results.	Action complete.				9/18
		MHRA DSU DC to ask web services about “advertising” yellow card scheme on Pattie. JM to prepare.	Ongoing – feed back in October.		DC	9/18	
		Guidance SG has asked JM to amend the valproate guideline.	Action complete.				9/18
		Correspondence received AM has written to Mr Oboh regarding the Esmya alert.	Action complete.				9/18
		Correspondence Received WH has checked that Radium 223 Dichloride is on formulary.	Action complete.				9/18
		AOB WH has added the UKMI religious beliefs Q&A paper to the agenda.	Action complete.				9/18
2018.09.05	New Product Requests	Patiromer Sorbitex Calcium (Veltassa®) – Hyperkalaemia – Prof S Bhandari The committee discussed the clinical evidence presented with	Rejected due to poor clinical evidence, but will	ML will write to applicants and WH will update	ML/ WH	10/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>the application and noted that the studies all had either no control or were against placebo. Some were open label, rather than double-blinded. It was also noted that the SMC does not recommend its use as there was not “a sufficiently robust economic analysis to gain acceptance”. SG informed the committee that a NICE TA was due to be published in March 2019.</p> <p>Isavuconazole (Cresemba®) – Invasive Aspergillosis/Invasive Mucormycosis – Dr P Lillie The application was made to treat patients who were intolerant to or who had treatment failure with other anti-mycotics which were predicted to be between 5 and 8 patients a year. Although there is no NICE TA for isavuconazole, NHS Wales and the SMC have both approved its use with restrictions. The committee discussed the evidence presented which demonstrated the product was not inferior to voriconazole or amphotericin and approved the application.</p> <p>5 -aminolevulinic acid (Gliolan®) – Pre op administration to facilitate resection of malignant gliomas – Mr Achawal The application was made in response to NICE guidance NG99 - Brain tumours (primary) and brain metastases in adults. Guidance recommends that two microscopes fitted with special filters are available during the procedure. Currently HEY has only one filter but has put together a business case to purchase a second.</p>	<p>be happy to revisit in March 2019 when the NICE TA is published.</p> <p>Approved.</p> <p>Approved.</p>	<p>formulary</p>			
2018.09.06	NICE Guidance - August 18	<p>NG102 Community pharmacies: promoting health and wellbeing.</p> <p>NG103 Flu vaccination: increasing uptake.</p> <p>TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine.</p> <p>TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer.</p> <p>TA537 Ixekizumab for treating active psoriatic arthritis after</p>	<p>Noted.</p> <p>On formulary.</p> <p>Lenvatinib is not on formulary.</p> <p>Alectinib not on formulary.</p> <p>On formulary for</p>	<p>ML to request application</p> <p>ML to request application</p> <p>Formulary to</p>	<p>ML</p> <p>ML</p> <p>WH</p>	<p>10/18</p> <p>10/18</p> <p>10/18</p>	<p>9/18</p> <p>9/18</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>inadequate response to DMARDs. OO agreed to speak with Rheumatology colleagues, regarding the extended NICE guidance.</p> <p>TA538 Dinutuximab beta for treating neuroblastoma.</p> <p>TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.</p>	<p>moderate to severe plaque psoriasis.</p> <p>Dinutuximab not on formulary.</p> <p>Not on formulary.</p>	<p>be update to say "in line with NICE"</p> <p>ML to request application</p> <p>ML to request application</p>	<p>ML</p> <p>ML</p>	<p>10/18</p> <p>10/18</p>	
2018.09.07	MHRA Drug Safety Update – August 2018	The risk of serious liver disease when using Esmya® (ullipristal acetate) was included in the update. KMCC asked that this be mentioned at HERPC as there is a Shared Care Framework for Uterine Fibroids which includes the drug. AM had already written to Mr Oboh.	Confirm that Esmya has been removed from SCF.	WH to liaise with AR & agenda for HERPC	WH	10/18	
2018.09.08	Minutes from SMPC	<p>None.</p> <p>HK informed the committee that ward H130 have introduced an area for medicine preparation and prescribing, which is separate from the ward/clinical notes area, in the hope that this will reduce the number of errors and DATIX reports.</p>	Noted.	No further action			9/18
2018.09.09	Minutes from HERPC	None.					
2018.09.10	Guidelines	<p>Parkinson's Disease Guideline</p> <p>The committee felt that the line "if an antiemetic is required prescribe domperidone" should come first, in BLOCKS. The line "do not prescribe medications which can worsen Parkinson's symptoms" stating which antiemetics should not be used should come afterwards.</p>	Approved with amendments.	SG to feed back to JM, including dissemination to Medicine & Surgery HGs	SG	10/18	
2018.09.11	What factors to consider when advising on	The paper raised a discussion not only on medicines suitable for a Halal diet but also for other religious beliefs which may have to be considered when prescribing medicines.	The committee felt that the paper should be	WH to agenda for next SMPC meeting	WH	10/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	medicines suitable for a Halal diet? – UKMI Q&A 381.3 Paper (26/02/16)		discussed at SMPC, and have wider discussion at OQC.				
2018.09.12	Correspondence Received	Normal Human Immunoglobulin availability and supply – NHSE SSC 1906 – 24/08/2018 POB informed the committee that there is a worldwide shortage of Normal Human Immunoglobulin and that regional panels will be set up to influence clinical practice and improve stewardship. HEY have cancelled patients who are deemed to be receiving treatment for less serious conditions. All existing patients are to be reviewed for dose and appropriateness.	Noted.	No further action			9/18
2018.09.13	Regional Medicines Optimisation Committee	31/07/18 - National RMOC Event on 9 October 2018 02/08/18 - Regional Medicines Optimisation Committee – London Update – July 2018 09/08/18 - Adalimumab resources to use with patients	Noted.	No further action			9/18
2018.09.14	Chairs approvals	<ul style="list-style-type: none"> Brincidofovir – Adenovirus – Dr Patrick Lillie Flunarizine - Sturge Weber Syndrome - Dr Sandhya Jose 	Noted.	No further action			9/18
2018.09.15	Issues to escalate to OQC	OQC to discuss “What factors to consider when advising on medicines suitable for a Halal diet?” – UKMI Q&A 381.3 Paper (26/02/16).	Discuss more widely at OQC	WH to add to OQC escalation report	WH	10/18	
2018.09.16	Any Other Business	KMcC informed the committee that AREDs formula and lidocaine plasters have now been discussed by both Hull & ER CCGs, who will both no longer commission AREDs and will only allow lidocaine plasters for the licensed indication (post-herpetic neuralgia).	Noted.	KMcC to provide documentation to D&T relating to CCG decision	KMcC	10/18	
2018.09.17	Date and Time of Next Meeting	Thursday 11 th October – 8.15 – 9.30am, Committee Room, HRI.					